A look at HIV/AIDS vaccines in development

In a report on the successes and failures of HIV/AIDS vaccine development over the last 30 years, our sister publication FierceBiotech Research details the various (and promising) approaches drugmakers are exploring for developing a vaccine to fight the virus. Article

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.